Crossmark

Docetaxel treatment together with CTLA-4 knockdown enhances reduction of cell viability and amplifies apoptosis stimulation of MCF-7 breast cancer cells

Crossref DOI link: https://doi.org/10.1007/s10616-024-00677-4

Published Online: 2024-12-12

Published Print: 2025-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hosseinkhani, Negar

Alipour, Shiva

Ghaffari Jolfayi, Amir

Aghebati-Maleki, Leili

Baghbani, Elham

Alizadeh, Nazila

Khaze, Vahid

Baradaran, Behzad
Funding

Funding for this research was provided by:

National Institute for Medical Research Development (996061)
License Information

Text and Data Mining valid from 2024-12-12

Version of Record valid from 2024-12-12
More Information

Article History

Received: 9 October 2024

Accepted: 2 December 2024

First Online: 12 December 2024

Declarations

:

: The authors declare no competing interests.

: Not Applicable.

: Not Applicable.

: Not Applicable.

Document is current

Any future updates will be listed below